PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression

Cancer Immunology, Immunotherapy · Published 2022-09-01 · Available online 29 Jan 2022 · Journal article · DOI 10.1007/s00262-021-03130-z · PMID: 35092481 · PMC · Cited by 69 (Crossref)

Authors (8)

A. Filippone, M. Lanza, D. Mannino, G. Raciti, C. Colarossi, D. Sciacca, S. Cuzzocrea, I. Paterniti

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

71

Issue

9

Pages

2067-2075

Year

2022

Citation

Filippone, A., Lanza, M., Mannino, D., et al. (2022). PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-03130-z

Related articles

• Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases · ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES · 2025 · Cites or is cited by this article
• Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma · Journal of the Egyptian National Cancer Institute · 2026 · Cites or is cited by this article
• Immunotherapy in Glioblastoma: An Overview of Current Status · Clinical Pharmacology: Advances and Applications · 2025 · Cites or is cited by this article
• Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation · Journal of Neuroimmune Pharmacology · 2025 · Cites or is cited by this article
• Unravelling inflammation-driven mechanisms in hepatocellular carcinoma: therapeutic targets and potential interventions · Egyptian Liver Journal · 2025 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

69